Laurus Labs Ltd.NSE: LAURUSLABS

Press Release May 02 2023

· Issued by Laurus Labs Ltd.

Filed with NSE ·

Laurus Labs Limited has informed the Exchange regarding a press release dated May 02, 2023, titled "Laurus Labs receives USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment".

View Attachment

6ix hasn’t read this filing yet.

Laurus Labs Ltd. on 6ix

Earlier from Laurus Labs

Later from Laurus Labs

All Laurus Labs news releases